Knight Therapeutics Stock Target Price
| KHTRF Stock | USD 3.73 0.07 1.84% |
Knight Therapeutics fundamentals help investors to digest information that contributes to Knight Therapeutics' financial success or failures. It also enables traders to predict the movement of Knight Pink Sheet. The fundamental analysis module provides a way to measure Knight Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Knight Therapeutics pink sheet.
Knight |
Knight Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Knight Therapeutics' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Knight Therapeutics could also be used in its relative valuation, which is a method of valuing Knight Therapeutics by comparing valuation metrics of similar companies.Knight Therapeutics is currently under evaluation in target price category among its peers.
Knight Fundamentals
| Return On Equity | -0.0266 | |||
| Return On Asset | -0.0133 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (0.08) % | |||
| Current Valuation | 354.32 M | |||
| Shares Outstanding | 113.96 M | |||
| Shares Owned By Insiders | 30.54 % | |||
| Shares Owned By Institutions | 12.90 % | |||
| Price To Earning | 15.30 X | |||
| Price To Book | 0.69 X | |||
| Price To Sales | 1.67 X | |||
| Revenue | 243.48 M | |||
| Gross Profit | 115.41 M | |||
| EBITDA | 58.22 M | |||
| Net Income | 15.68 M | |||
| Cash And Equivalents | 147.08 M | |||
| Cash Per Share | 1.28 X | |||
| Total Debt | 9.27 M | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 2.54 X | |||
| Book Value Per Share | 7.50 X | |||
| Cash Flow From Operations | 44.62 M | |||
| Earnings Per Share | (0.04) X | |||
| Number Of Employees | 660 | |||
| Beta | 0.5 | |||
| Market Capitalization | 444.73 M | |||
| Total Asset | 991.89 M | |||
| Z Score | 28.8 | |||
| Net Asset | 991.89 M |
About Knight Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Knight Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Knight Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Knight Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Knight Pink Sheet
Knight Therapeutics financial ratios help investors to determine whether Knight Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.